Bruns Ingmar 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Dec 3, 2024
Insider Transaction Report
Form 4
Bruns Ingmar
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-12-02+712,650→ 712,650 totalExercise: $3.66Exp: 2034-12-02→ Common Stock (712,650 underlying)
Footnotes (1)
- [F1]The options will vest over a four-year period as follows: 25% of the options will vest on November 13, 2025, with the remaining 75% vesting in substantially equal monthly installments thereafter until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.